PET developer Positron of Houston last week completed a privatestock offering that solves a cash-flow problem that has doggedthe firm since late last year (SCAN 2/28/96). Positron issuedconvertible preferred stock and purchase warrants to raise
PET developer Positron of Houston last week completed a private
stock offering that solves a cash-flow problem that has dogged
the firm since late last year (SCAN 2/28/96). Positron issued
convertible preferred stock and purchase warrants to raise net
proceeds of $3 million, which will be used for working capital,
to make payments on PET components, and to increase its tangible
assets. The offering enabled Positron to meet NASDAQ's tangible
net asset requirements and maintain the company's listing on the
exchange.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.